References
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. DOI:10.1016/S0140-6736(22)02033-5
- World Health Organisation. Diabetes. Available at https://www.who.int/health-topics/diabetes#tab=tab_1 [Last accessed 23 Jan, 2023]
- World Health Organisation. Obesity and overweight. Available at https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [Last accessed 23 Jan, 2023]
- Perdoma CM, Cohen RV, Sumithran P, et al. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet. 2023;401(10382):1116–1130. DOI: 10.1016/S0140-6736(22)02403-5. Published online.
- Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 2021;33:833–844.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;383(6):503–515. DOI: 10.1056/NEJMoa2107519
- Cabrera O, Ficorilli J, Shaw J, et al. Intra-islet glucagon confers β-cell glucose competence for first-phase insulin secretion and favors GLP-1R stimulation by exogenous glucagon. J Biol Chem. 2022;298(2):101484. DOI:10.1016/j.jbc.2021.101484
- Coskun C, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247. DOI:10.1016/j.cmet.2022.07.013
- Caruso I, Marrano N, Biondi G, et al. Glucagon in type 2 diabetes: friend or foe? Diabetes Metab Res Rev. 2023 Jan 13;39(3):e3609. Online ahead of print. DOI:10.1002/dmrr.3609
- Ambery P, Parker VE, Stumvoll M, et al. MED10382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391(10140):2607–2618. DOI:10.1016/S0140-6736(18)30726-8
- Di Prospero NA, Yee J, Frustaci ME, et al. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: a randomized dose-ranging study. Clin Obes. 2021;11(2):e12433. DOI:10.1111/cob.12433
- Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286. DOI:10.1016/S2213-8587(18)30024-X
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. DOI:10.1056/NEJMoa2206038
- US Food & Drug Administration. FDA approves novel, dual-targeted treatment for type 2 diabetes https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes [Last accessed 25 Jan, 2023]
- Lilly. Lilly receives U.S. FDA fast track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities. https://investor.lilly.com/news-releases/news-release-details/lilly-receives-us-fda-fast-track-designation-tirzepatide [Last accessed 25 Jan, 2023]
- ClinicalTrials.gov. A study of LY3437943 in participants with type 2 diabetes. https://beta.clinicaltrials.gov/study/NCT04867785?cond=retatrutide&rank=1 [Last accessed 24 Jan, 2023]
- ClinicalTrials.gov. A study of LY3437943 in participants who have obesity or are overweight. https://beta.clinicaltrials.gov/study/NCT04881760?cond=retatrutide&rank=4 [Last accessed 24 Jan, 2023]